OnKure Therapeutics, Inc.
OKUROnKure Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of precision medicines for cancers and vascular overgrowth syndromes.
Earnings
Next report
Aug 11, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
OnKure Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of precision medicines for cancers and vascular overgrowth syndromes. The company utilizes a structure-based drug design platform to create small molecule inhibitors that selectively target specific genetic mutations while sparing wild-type enzymes. This approach aims to maximize therapeutic efficacy and minimize off-target toxicities associated with non-selective inhibition.
OnKure is a clinical-stage developer of next-generation PI3Kα inhibitors, positioning itself as a more selective and less toxic alternative to first-generation therapies.
Questions, answered.
- What is OnKure Therapeutics, Inc.'s market cap?
- OnKure Therapeutics, Inc. (OKUR) has a market capitalization of $163.6M and trades on XNAS.
- Who are OnKure Therapeutics, Inc.'s competitors?
- OnKure Therapeutics, Inc.'s key competitors include Pfizer, Prelude Therapeutics Incorporated, Eikon Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is OnKure Therapeutics, Inc. headquartered?
- OnKure Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2024.